NasdaqGM - Delayed Quote USD

Nemaura Medical Inc. (NMRD)

0.0311 -0.0039 (-11.14%)
At close: May 10 at 3:58 PM EDT
Loading Chart for NMRD
DELL
  • Previous Close 0.0350
  • Open 0.0400
  • Bid --
  • Ask --
  • Day's Range 0.0311 - 0.0400
  • 52 Week Range 0.0290 - 1.2500
  • Volume 105,798
  • Avg. Volume 42,630
  • Market Cap (intraday) 898,771
  • Beta (5Y Monthly) 0.03
  • PE Ratio (TTM) --
  • EPS (TTM) -0.3900
  • Earnings Date Jul 12, 2024 - Jul 16, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 1.50

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

nemauramedical.com

36

Full Time Employees

March 31

Fiscal Year Ends

Recent News: NMRD

Performance Overview: NMRD

Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

NMRD
85.80%
S&P 500
9.49%

1-Year Return

NMRD
95.77%
S&P 500
26.79%

3-Year Return

NMRD
99.64%
S&P 500
23.39%

5-Year Return

NMRD
99.66%
S&P 500
81.93%

Compare To: NMRD

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NMRD

Valuation Measures

Annual
As of 2/9/2024
  • Market Cap

    898.77k

  • Enterprise Value

    20.40M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    712.42

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    7.18k

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -81.19%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -10.65M

  • Diluted EPS (ttm)

    -0.3900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    137.42k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -10.07M

Research Analysis: NMRD

Company Insights: NMRD

Research Reports: NMRD

People Also Watch